PROVIDENCE – Troutman Pepper Locke advised MindImmune Therapeutics, Inc., a Rhode Island-based company started at the University of Rhode Island, in securing its $30 million Series A financing. The funds will support the company through an investigational new drug application and then into the clinic. For more information, see the press release.
The Troutman Pepper Locke team that advised MindImmune was led by Chris Graham and included Nicole Chakraborty and Adam Millard.
Troutman Pepper Locke is very active in the emerging company and venture capital communities, advising clients through every stage of their life cycle, from formation through financing and growth, and their eventual merger, acquisition, or IPO exit. For select companies, the firm also offers the unique Troutman SEED™ program. This development program combines the resources of an experienced, multidisciplinary team into an affordable package for startups, early-stage, and fast-growing companies, providing them with comprehensive legal counsel, mentoring, relationship-building opportunities, and more.
Troutman Pepper Locke
Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.